10-Q: Delcath Systems Reports First Quarter 2024 Results, Driven by HEPZATO Launch

Delcath Systems saw a significant increase in revenue in the first quarter of 2024 due to the commercial launch of HEPZATO in the U.S. and increased demand for CHEMOSAT in Europe.

Summary

• Delcath Systems reported a net loss of $11.1 million for the first quarter of 2024, compared to a net loss of $9.0 million for the same period in 2023.
• The company's total revenue increased to $3.1 million, up from $0.6 million in the first quarter of 2023, driven by the launch of HEPZATO in the U.S. and increased CHEMOSAT sales in Europe.
• Operating expenses totaled $12.5 million, with research and development expenses at $3.7 million and selling, general, and administrative expenses at $8.8 million.
• The company's cash and cash equivalents were $11.8 million, with short-term investments of $15.4 million as of March 31, 2024.
• Delcath used $9.6 million in operating activities and $3.1 million for principal payments during the quarter.
• The company has a going concern uncertainty due to its history of losses and the need for additional capital.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has achieved a significant milestone with the commercial launch of HEPZATO and increased revenue, it is still operating at a loss and faces significant financial challenges. The going concern uncertainty and need for additional capital are concerning, but the revenue growth and product potential are positive.

Positives

• The commercial launch of HEPZATO in the U.S. has begun, generating $2.0 million in revenue.
• CHEMOSAT sales in Europe continue to contribute to revenue, with $1.1 million in sales.
• Gross profit increased significantly to $2.2 million, indicating improved profitability on sales.
• The company has secured a supply of raw materials for HEPZATO to meet the first year of anticipated demand.

Negatives

• The company reported a net loss of $11.1 million for the quarter.
• Operating expenses increased to $12.5 million, driven by commercial launch activities.
• The company used $9.6 million in cash for operating activities during the quarter.
• There is a going concern uncertainty due to the company's history of losses and the need for additional capital.

Risks

• The company faces risks associated with the successful commercialization of HEPZATO and CHEMOSAT.
• There is uncertainty regarding the broad adoption of the products by physicians and consumers.
• The company is subject to significant competition in the biopharmaceutical industry.
• The company may need to raise additional capital, which may not be on favorable terms.
• There is a risk of delays in the activation of sites to administer HEPZATO.
• The company's ability to access existing cash, cash equivalents and investments may be threatened if additional banks and financial institutions enter receivership or become insolvent.

Future Outlook

The company plans to begin one or more studies of HEPZATO KIT to treat other cancers in the liver in 2024, and expects to generate clinical data for CHEMOSAT and HEPZATO to support increased clinical adoption and reimbursement.

Management Comments

• The company intends to manage supply chain risk through stockpiled inventory and contracting with multiple suppliers for critical components.
• The company believes that HEPZATO has the potential to treat cancers in the liver, such as metastatic colorectal cancer, metastatic neuroendocrine tumors, metastatic breast cancer and intrahepatic cholangiocarcinoma.

Industry Context

The company operates in the interventional oncology space, focusing on liver-directed cancer treatments. The launch of HEPZATO in the U.S. is a significant milestone, and the company is working to expand its clinical data and market reach for both HEPZATO and CHEMOSAT.

Comparison to Industry Standards

• Delcath's revenue growth is notable compared to other early-stage biotech companies launching their first products.
• The company's operating expenses are high, which is typical for companies in the commercialization phase of a new drug/device combination product.
• The company's cash burn rate is a concern, and it will need to manage its finances carefully to achieve profitability.
• Compared to companies like Sirtex Medical (acquired by CDH Investments), which also focuses on liver-directed cancer therapies, Delcath is at an earlier stage of commercialization but has a similar focus on a combination drug/device approach.
• Other companies in the oncology space, such as Exelixis and Immunomedics (acquired by Gilead), have demonstrated the potential for significant revenue growth after successful product launches, which Delcath is aiming to replicate.

Legal Proceedings

• The company is in a settlement agreement with medac GmbH regarding a dispute over a License, Supply and Marketing Agreement.

Stakeholder Impact

• Shareholders face the risk of dilution from potential future capital raises.
• Employees are impacted by the company's financial performance and potential restructuring.
• Customers (hospitals and treatment centers) are impacted by the availability and adoption of HEPZATO and CHEMOSAT.
• Suppliers are impacted by the company's ability to meet its financial obligations and purchase agreements.
• Creditors are impacted by the company's ability to repay its debts.

Next Steps

• The company plans to initiate one or more studies of HEPZATO KIT to treat other cancers in the liver in 2024.
• The company will continue to generate clinical data for CHEMOSAT and HEPZATO to support increased clinical adoption and reimbursement.
• The company will need to manage its cash burn and potentially raise additional capital to fund its operations.

Key Dates

Keywords

HEPZATO, CHEMOSAT, Uveal Melanoma, Liver Cancer, Interventional Oncology, Melphalan, FDA Approval, Commercial Launch, Financial Results, Clinical Trials